doi: 10.3389/fphar.2025.1601712 Received 28 March 2025 Accepted 27 May 2025 Published 23 June 2025 Volume 16 - 2025 Edited by Ashish Mehta, Garvan Institute of Medical Research, Australia Reviewed by Ankul Singh S, ACS Medical College and Hospital, India Prabhash Nath Tripathi, University of Arkansas for Medical Sciences, United States Updates Copyright 2025 Aktary, Jeong, Oh, Shin, Sung, Rahman, Ramos Santiago, Choi, Song, Nurkolis, Ribeiro, Park and Kim
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
The science and translation of lactate shuttle theory
To do this, we paired our own personal tests of each formula with expert guidance and reviewer insights to determine which we would recommend to you